Trimegestone. Treatment of postmenopausal syndrome prevention of osteoporosis oral contraceptive progestogen

Drugs of the Future

Volumn 25, Issue 5, 2000, Pages 465-473

  Sorbera, L A ^a   Leeson, P A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

17 BETA [2 HYDROXYPROPIONYL] 17 METHYLESTRA 4,9 DIEN 3 ONE; 17 BETA ][LACTOYL] 17 METHYLESTRA 4,9 DIEN 3 ONE; ORAL CONTRACEPTIVE AGENT; TRIMEGESTONE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; DRUG SYNTHESIS; ESTROGEN SYNTHESIS; HORMONE SUBSTITUTION; OSTEOCLAST; OSTEOPOROSIS; POSTMENOPAUSE; RECEPTOR BINDING; SUBSTITUTION THERAPY;

EID: 0034096266     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.05.577267     Document Type: Article

References (27)

1. Crocq, V., Masson, C., Winter, J., Richard, C., Lemaitre, G., Lenay, J., Vivat, M., Buendia, J., Prat, D. Synthesis of trimegestone: The first industrial application of Bakers' yeast mediated reduction of a ketone. Org Process Res Dev 1997, 1: 2-13.
2. Buendia, J., Crocq, V., Masson, C., Prat, D., Vivat, M. (Roussel-Uclaf). A new process for the preparation of 20-keto-21alpha-hydroxy steroid cpds. and intermediates thereof. EP 0574317, FR 2692267, JP 1994065283, US 5399685.
3. Coussediere, D. (Roussel-Uclaf). Novel 3,20-dioxo-4,9-diene-21-hydroxy steroid cpds., process for their preparation, their use in medicines and pharmaceutical compsns. containing them. DK 163361, DK 165637, EP 0007823, EP 0046001, ES 482112, FR 2430953, IE 49457, JP 1980015475, JP 1988033395, US 4273771.
4. Buendia, J., Godard, J.-Y., Mackiewicz, P., Richard, C. (Roussel-Uclaf). New method of production of 20-keto 21(S)-hydroxy steroid cpds. and intermediates thereof. EP 581649, FR 2694007, JP 1994181796, US 5384419.
5. Belchetz, P.E. Drug therapy: Hormonal treatment of postmenopausal women. New Engl J Med 1994, 330: 1062-71.
6. Greendale, G.A., Lee, N.P., Arriola, E.R. The menopause. Lancet 1999, 353: 571-80.
7. Philibert, D., Bouchoux, F., Degryse, M., Lecaque, D., Petit, F., Gaillard, M. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999, 13: 316-26.
8. Abendstein, B., Marth, C., Daxenbichler, G. Evaluation of RU-27987 as a ligand to determine the progesterone receptor. Clin Chim Acta 1987, 168: 47-54.
9. Lundeen, S.G., Zhang, Z., Zhu, Y., Carver, J.M., Ponce-de-Leon, H., Winneker, R.C. In vivo characterization of trimegestone: A new potent, selective steroidal progestin. 81st Annu Meet Endocr Soc (June 12-15, San Diego) 1999, Abst P1-256.
10. Moguilewsky, M., Philibert, D., Bouton, M.-M., Raynaud, J.P. RU-27987: 21S-Hydroxy metabolite of R-5020 for the assay of the nuclear progestin receptor. Application to brain tumor. J Steroid Biochem 1984, 19(Suppl.): Abst 378.
11. Pomper, M.G., Pinney, K.G., Carlson, K.E., van Brocklin, H., Mathias, C.J., Welch, M.J., Katzenellenbogen, J.A. Target tissue uptake selectivity of three fluorine substituted progestins: Potential imaging agents for receptor-positive breast tumors. Nucl Med Biol 1990, 17: 309-19.
12. ® (RU27987), a 3-keto-Δ4,9(10)-19-norsteroid drug. Bioorg Med Chem 1999, 7: 2329-41.
13. Ross, D., Godfree, V., Cooper, A., Pryse-Davies, J., Whitehead, M.I. Endometrial effects of three doses of trimegestone, a new orally active progestogen, on the postmenopausal endometrium. Maturitas 1997, 28: 83-8.
14. Al-Azzawi, F., Wahab, M., Thompson, J., Whitehead, M., Thompson, W. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: A dose-ranging study. Hum Reprod 1999, 14: 636-41.
15. Wahab, M., Thompson, J., Hamid, B., Deen, S., Al-Azzawi, F. Endometrial histomorphometry of trimegestone-based sequential hormone replacement therapy: A weighted comparison with the endometrium of the natural cycle. Hum Reprod 1999, 14: 2609-18.
16. Wahab, M., Thompson, J., Al-Azzawi, F. The distribution of endometrial leukocytes and their proliferation markers in trimegestone-treated postmenopausal women compared to the endometrium of the natural cycle: A dose-ranging study. Hum Reprod 1999, 14: 1201-6.
17. van Baal, W.M., Emeis, J.J., Kenemans, P., Kessel, H., Peters-Muller, E.R., Schalkwijk, C.G., van der Mooren, M.J., Stehouwer, C.D. Short-term hormone replacement therapy: Reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 1999, 29: 913-21.
18. van Baall, W.M., Smolders, R.G., van der Mooren, M.J., Teerlink, T., Kenemans, P. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 1999, 94: 485-91.
19. American Home Products Corp. Annual Report 1999.
20. Gast, M.J. (American Home Products Corp.). Oral contraceptive. WO 9804246.
21. Gast, M.J. (American Home Products Corp.). Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen. WO 9804265.
22. Gast, M.J. (American Home Products Corp.). Oral contraceptive. WO 9804266.
23. Gast, M.J. (American Home Products Corp.). Progestin/ estrogen oral contraceptive. WO 9804267.
24. Gast, M.J. (American Home Products Corp.). Oral contraceptive. WO 9804268.
25. Gast, M.J. (American Home Products Corp.). Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen. WO 9804269.
26. Gast, M.J. (American Home Products Corp.). Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin. WO 9913882.
27. Gast, M.J. (American Home Products Corp.). Oral contraceptives. US 5888543.